Para-hydroxytranylcypromine: presence in rat brain and heart following administration of tranylcypromine and an N-cyanoethyl analogue

  • A. J. Nazarali
  • G. B. Baker
  • R. T. Coutts
  • A. J. Greenshaw
Original Papers


para-Hydroxytranylcypromine (p-OHTCP) has recently been unequivocally identified in our laboratory as a metabolite of the antidepressant tranylcypromine (TCP). In the study reported here, we have determined brain and heart levels ofp-OHTCP in the rat after intraperitoneal administration of a 0.1 mmol/kg dose of TCP or N-(2-cyanoethyl)tranylcypromine (CE-TCP). The animals were killed at 5, 15, 30, 60, 120 or 240 min after drug administration and the tissues (brain and heart) rapidly dissected out. The tissues were frozen in isopentane on solid carbon dioxide and stored at −20°C until time of analysis. Tissue levels ofp-OHTCP, TCP and CE-TCP were determined after aqueous pentafluorobenzoylation by conducting analyses with a gas-liquid chromatograph equipped with a fused silica (SE-54) capillary column and an electron-capture detector. Our results show that substantial concentrations ofp-OHTCP were present in both brain and heart after TCP and CE-TCP administration. Higher levels ofp-OHTCP were present in the brain than in the heart after TCP treatment, but this situation was reversed with the CE-TCP-treated rats. Sincep-OHTCP has been shown to retain some MAO-inhibiting properties and to have effects on uptake of catecholamines and serotonin it could therefore contribute to the pharmacological profile of TCP.


Brain heart monoamine oxidase inhibitor para-hydroxytranylcypromine tranylcypromine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Martindale: The Extra Pharmacopoeia, 28th ed., (1982): (eds., Reynolds J.E.F. and Prasad A.B.), pp. 131–132. Pharmaceutical Press, London.Google Scholar
  2. 2.
    Fuentes J.A., Oleshansky M.A. and Neff N.H. (1976): Comparison of the apparent antidepressant activity of (-) and (+) tranylcypromine in an animal model.Biochem. Pharmacol. 25, 801–804.CrossRefPubMedGoogle Scholar
  3. 3.
    Calverley D.G., Baker G.B., Coutts R.T. and Dewhurst W.G. (1981): A method for measurement of tranylcypromine in rat brain regions using gas chromatography with electron-capture detection.Biochem. Pharmacol. 30, 861–867.CrossRefPubMedGoogle Scholar
  4. 4.
    Nazarali A.J., Baker G.B., Coutts R.T. and Wong T.F.J. (1987): N-(2-cyanoethyl)tranylcypromine, a potential prodrug of tranylcypromine: its disposition and interaction with catecholamine neurotransmitters in brain.Pharm. Res. 4, 16–20.CrossRefPubMedGoogle Scholar
  5. 5.
    Beckett A.H., Shenoy E.V.B, and Salmon J.A. (1972): The influence of replacement of the N-ethyl group by the cyanoethyl group on the absorption, distribution and metabolism of (+)-ethylamphetamine in man.J. Pharm. Pharmacol.24, 194–202.PubMedGoogle Scholar
  6. 6.
    Tognoni G., Morselli P.L. and Garattini S. (1972): Amphetamine concentrations in rat brain and human urine after fenproporex administration. Eur. J. Pharmacol.20, 125–126.CrossRefPubMedGoogle Scholar
  7. 7.
    Nazarali A.J., Baker G.B., Coutts R.T. and Pasutto F.M. (1983): Amphetamine in rat brain after intraperitoneal injection of N-alkylated analogues.Prog. Neuropsychopharmacol. & Biol. Psychiat..7, 813–816.CrossRefGoogle Scholar
  8. 8.
    Coutts R.T., Nazarali A.J., Baker G.B. and Pasutto F.M. (1986): Metabolism and disposition of N-(2-cyanoethyl) amphetamine (fenproporex) and amphetamine: study in the rat brain.Can. J. Physiol. Pharmacol. 64, 724–728.PubMedGoogle Scholar
  9. 9.
    Warembourg H. and Jaillard J. (1968): Expérimentation clinique due fenproporex dans le traitment des obésités.Lille Med 13, Suppl. 273.PubMedGoogle Scholar
  10. 10.
    Hertel G. and Fallot-Burghardt W. (1978): Treatment of obese female patients with fenproporex within the framework of gynecologic practice.Fortschr. Med 96, 2380–2382.PubMedGoogle Scholar
  11. 11.
    Martindale: The Extra Pharmacopoeia, (1982): 28th ed., (eds., Reynolds J.E.F. and Prasad A.B.), pp. 15–70. Pharmaceutical Press, London.Google Scholar
  12. 12.
    Baker G.B., Hampson D.R., Coutts R.T. Micetich R.G., Hall T.W. and Rao T.S. (1986): Detection and quantitation of a ring hydroxylated metabolite of the antidepressant drug tranylcypromine.J. Neural. Transm., 65, 233–243.CrossRefPubMedGoogle Scholar
  13. 13.
    Winer B.J. (1971): Statistical Principles in Experimental Design. Second Edition, pp. 1–907, McGraw-Hill Book Company, N.Y.Google Scholar
  14. 14.
    Gibaldi M. and Perrier D. (1982): inPharmacokinetics, Second Edition, Revised and Expanded, vol. 15, pp. 1–494. Marcel Dekker, Inc., New York.Google Scholar
  15. 15.
    Coutts R.T. and Dawson G.W. (1977): Urinary excretion of phenolic metabolites of N-(n-propyl)amphetamine in man.Res. Commun. Chem. Pathol. Pharmacol. 17, 349–352.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • A. J. Nazarali
    • 1
    • 2
  • G. B. Baker
    • 1
    • 2
  • R. T. Coutts
    • 1
    • 2
  • A. J. Greenshaw
    • 1
    • 2
  1. 1.PMHAC Research Unit, Faculty of Pharmacy and Pharmaceutical SciencesUniversity of AlbertaEdmontonCanada
  2. 2.Department of Psychiatry, 1E1.01 Mackenzie CentreUniversity of AlbertaEdmontonCanada

Personalised recommendations